Pricing and reimbursement of orphan drugs: The need for more transparency

Orphanet Journal of Rare Diseases

Volumn 6, Issue 1, 2011, Pages

  Simoens, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG MARKETING; ECONOMIC EVALUATION; HEALTH CARE; HUMAN; REIMBURSEMENT; REVIEW; ARTICLE; COST CONTROL; DRUG MANUFACTURE; ECONOMICS; HEALTH CARE COST; HEALTH INSURANCE; PHARMACOECONOMICS; RARE DISEASE;

COST CONTROL; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; HEALTH EXPENDITURES; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; INSURANCE, PHARMACEUTICAL SERVICES; ORPHAN DRUG PRODUCTION; RARE DISEASES;

EID: 79958849417     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-6-42     Document Type: Review

References (38)

1. Regulation (EC) No 141/2000 of the European Parliament and the Council of 16 December 1999 on orphan medicinal products. European Commission, Official Journal of the European Communities 2000 L 18/1
2. The portal for rare diseases and orphan drugs. Orphanet, Orphanet 2011 9 5 2011. Ref Type: Electronic Citation
3. Phase I: overview of the conditions for marketing orphan drugs in Europe. Alcimed. Study on orphan drugs, Koning Boudewijnstichting 2006 18 3 2010. Ref Type: Electronic Citation
4. Health technology assessment policy governing orphan diseases and orphan medicines. A Denis S Simoens C Fostier L Mergaert I Cleemput, Brussels, Belgian Health Care Knowledge Centre 2009 Ref Type: Report
5. Rare diseases, orphan drugs and their regulation: questions and misconceptions. E Tambuyzer, Nat Rev Drug Discov 2010 9 921 929 10.1038/nrd3275 21060315
6. Adopting an orphan. A Rinaldi, EMBO Rep 2005 6 507 510 10.1038/sj.embor.7400450 15940282 (Pubitemid 40973956)
7. Drugs for rare diseases - orphan designation status influences price. E Picavet M Dooms D Cassiman S Simoens, Appl Health Econ Health Policy 2011 9 1 5 10.2165/11531800-000000000-00000 21174479
8. Drugs for rare diseases: paying for innovation. A Hollis, Health services restructuring in Canada: new evidence and new directions Montreal: McGill-Queen's University Press, Beach C, 2006
9. Potential interactions of the Orphan Drug Act and pharmacogenomics: a flood of orphan drugs and abuses? D Loughnot, Am J Law Med 2005 31 365 380 16146295 (Pubitemid 41192518)
10. Exploring emerging technologies using metaphors - a study of orphan drugs and pharmacogenomics. W Boon E Moors, Soc Sci Med 2008 66 1915 1927 10.1016/j.socscimed.2008.01.012 18308439
11. Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products. JW Dear P Lilitkarntakul DJ Webb, Br J Clin Pharmacol 2006 62 264 271 10.1111/j.1365-2125.2006.02654.x 16934041 (Pubitemid 44215525)
12. Pharmaceutical Price Regulation Scheme. Department of Health, London, Department of Health 2010 18 3 2010. Ref Type: Report
13. AWMSG policy on ultra-orphan drugs. All Wales Medicines Strategy Group, All Wales Medicines Strategy Group 2011 21 2 2011. Ref Type: Electronic Citation
14. Assessing the economic challenges posed by orphan drugs. MF Drummond DA Wilson P Kanavos P Ubel J Rovira, Int J Technol Assess Health Care 2007 23 36 42 17234015 (Pubitemid 46648298)
15. The portal for rare diseases and orphan drugs. Orphanet, Orphanet 2010 11 6 2010. Ref Type: Electronic Citation
16. Orphan drugs. Relating price determination to disease prevalence. A Messori A Cicchetti L Patregani, BMJ 2010 341 4615 10.1136/bmj.c4615 20736283
17. The problem of orphan drugs. RE Ferner DA Hughes, BMJ 2010 341 6456 10.1136/bmj.c6456 21081597
18. Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency. J Regnstrom F Koenig B Aronsson T Reimer K Svendsen S Tsigkos,, et al. Eur J Clin Pharmacol 2010 66 39 48 10.1007/s00228-009-0756-y 19936724
19. The orphan drug backlash. T Maeder, Sci Am 2003 288 80 87 12701333
20. Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. T Attina R Camidge DE Newby DJ Webb, Heart 2005 91 825 831 10.1136/hrt.2004.053991 15894792 (Pubitemid 40769240)
21. Prices and availability of biopharmaceuticals: an international comparison. PM Danzon MF Furukawa, Health Aff (Millwood) 2006 25 1353 1362 10.1377/hlthaff.25.5.1353 (Pubitemid 44497636)
22. Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy. JT Clarke, CMAJ 2006 174 189 190 10.1503/cmaj.050706 16415465 (Pubitemid 43166273)
23. A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry. A Owen J Sprinks A Meehan T Robb M Hardy D Kwasha, Journal of Medical Economics 2008 11 235 243 19450082
24. National Institute for Clinical Excellence and its value judgments. MD Rawlins AJ Culyer, BMJ 2004 329 224 227 10.1136/bmj.329.7459.224 15271836 (Pubitemid 39013284)
25. Orphan drugs and the NHS: should we value rarity? C McCabe K Claxton A Tsuchiya, BMJ 2005 331 1016 1019 10.1136/bmj.331.7523.1016 16254305 (Pubitemid 41552456)
26. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996). B George A Harris A Mitchell, Pharmacoeconomics 2001 19 1103 1109 10.2165/00019053- 200119110-00004 11735677 (Pubitemid 33135698)
27. Drugs for exceptionally rare diseases: do they deserve special status for funding? DA Hughes B Tunnage ST Yeo, QJM 2005 98 829 836 10.1093/qjmed/hci128 16203824 (Pubitemid 41631334)
28. National Institute for Health and Clinical Excellence, Appraising life-extending, end of life treatments London: National Institute for Health and Clinical Excellence 2009
29. QALY maximisation and people's preferences: a methodological review of the literature. P Dolan R Shaw A Tsuchiya A Williams, Health Econ 2005 14 197 208 10.1002/hec.924 15386656 (Pubitemid 40253634)
30. Citizens Council Report Ultra Orphan Drugs. National Institute for Health and Clinical Excellence, National Institute for Health and Clinical Excellence 2005 19 3 2010. Ref Type: Electronic Citation
31. Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67. AS Desser D Gyrd-Hansen JA Olsen S Grepperud IS Kristiansen, BMJ 2010 341 4715 10.1136/bmj.c4715 20861122
32. 10 years of NICE: still growing and still controversial. P Littlejohns S Garner N Doyle F Macbeth D Barnett C Longson, Lancet Oncol 2009 10 417 424 10.1016/S1470-2045(09)70077-4 19341973
33. A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1. M Connock A Juarez-Garcia E Frew A Mans J Dretzke A Fry-Smith,, et al. Health Technol Assess 2006 10 ii 113 17134598
34. Pharmaceutical risk-sharing agreements. JP Cook JA Vernon R Manning, Pharmacoeconomics 2008 26 551 556 10.2165/00019053-200826070-00002 18563946 (Pubitemid 351871550)
35. Orphan Drugs Risk Share. Scottish Medicines Consortium, Scottish Medicines Consortium 2010 19 3 2010. Ref Type: Electronic Citation
36. Cost effective provision of disease modifying therapies for people with multiple sclerosis. Department of Health, 2002 19 3 2010. Ref Type: Report
37. Multiple sclerosis risk sharing scheme: a costly failure. J Raftery, BMJ 2010 340 1672 10.1136/bmj.c1672 20522654
38. Choosing the right incentive strategy for research and development in neglected diseases. SM Maurer, Bull World Health Organ 2006 84 376 381 10.2471/BLT.06.029835 16710547